← Leaderboards
Scott D Larsen
University Of Michigan At Ann Arbor
$5,478,139
Attributed
$8,597,440
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2009–19$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$8,597,440 · 7
By mechanism
R01$5,589,876 · 3
UH3$1,534,047 · 1
R21$842,395 · 2
UH2$631,122 · 1
Top collaborators
- James Alan Shayman8 shared
- Ronald J Buckanovich3 shared
- Vernon Bruce Carruthers2 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- James Alan Shayman$8,158,958
Others in their field
Top investigators on “Inhibitor/Antagonist”
- John M Lachin · George Washington University$117,867,649
- David M Nathan · Massachusetts Institute Of Technology$117,867,649
- Randall J Bateman · Washington University$110,978,751
- David Heimbrook · Leidos Biomedical Research, Inc.$72,139,282
- Keri Hammel · The Emmes Company, Llc$53,700,408
- Walter John Curran · Thomas Jefferson University$32,790,605
Research focus
Inhibitor/AntagonistPropertyDesignAnalogIn VivoSeriesBaseDrug KineticsIn VitroLeadSmall MoleculeKidneyProteinsEffective TherapyBlood - Brain Barrier AnatomyGlucosylceramidesCatabolismGlycosphingolipidosesEnzyme Replacement TherapyLysosomal Storage DiseasesCeramide GlucosyltransferasePermeabilityGlycosphingolipidsInnovation
Grant awards (18)
Isozyme-selective ALDH Inhibitors for Sensitizing Ovarian Cancer Stem-like Cells to Chemotherapy$572,426
R01 · FY2019 · CA · contact PI
The Development of Small Molecule Inhibitors for Gaucher Disease Type 3$1
UH3 · FY2019 · NS
Isozyme-selective ALDH Inhibitors for Sensitizing Ovarian Cancer Stem-like Cells to Chemotherapy$603,477
R01 · FY2018 · CA · contact PI
Rational design of CNS-permeable cathepsin L inhibitors for treatment of chronic toxoplasmosis$227,976
R21 · FY2018 · AI
The Development of Small Molecule Inhibitors for Gaucher Disease Type 3$1
UH3 · FY2018 · NS
The Development of Small Molecule Inhibitors for Gaucher Disease Type 3$750,989
UH3 · FY2017 · NS
Isozyme-selective ALDH Inhibitors for Sensitizing Ovarian Cancer Stem-like Cells to Chemotherapy$636,181
R01 · FY2017 · CA · contact PI
Rational design of CNS-permeable cathepsin L inhibitors for treatment of chronic toxoplasmosis$193,750
R21 · FY2017 · AI
The Development of Small Molecule Inhibitors for Gaucher Disease Type 3$783,056
UH3 · FY2016 · NS
Inhibition of the Rho/MRTF/SRF Pathway as a New Treatment for Systemic Sclerosis$631,620
R01 · FY2016 · AR · contact PI
Inhibition of the Rho/MRTF/SRF Pathway as a New Treatment for Systemic Sclerosis$651,097
R01 · FY2015 · AR · contact PI
The Development of Small Molecule Inhibitors for Gaucher Disease Type 3$631,122
UH2 · FY2015 · NS
Novel Probes for Studying Treatment of CNS-based Lysosomal Storage Diseases$589,896
R01 · FY2015 · HD · contact PI
Inhibition of the Rho/MRTF/SRF Pathway as a New Treatment for Systemic Sclerosis$655,452
R01 · FY2014 · AR · contact PI
Novel Probes for Studying Treatment of CNS-based Lysosomal Storage Diseases$607,880
R01 · FY2014 · HD · contact PI
Novel Probes for Studying Treatment of CNS-based Lysosomal Storage Diseases$641,847
R01 · FY2013 · HD · contact PI
Design of CNS-Permeable Agents for the Treatment of Lipid Storage Diseases$227,544
R21 · FY2010 · NS · contact PI
Design of CNS-Permeable Agents for the Treatment of Lipid Storage Diseases$193,125
R21 · FY2009 · NS · contact PI